Welcome to the UPF Digital Repository

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing

Show simple item record

dc.contributor.author Conde, Esther
dc.contributor.author Rojo, Federico
dc.contributor.author Gómez, Javier
dc.contributor.author Enguita, Ana Belen
dc.contributor.author Abdulkader, Ihab
dc.contributor.author González, Ana
dc.contributor.author Lozano, Dolores
dc.contributor.author Mancheño, Nuria
dc.contributor.author Salas, Clara
dc.contributor.author Salido Galeote, Marta
dc.contributor.author Salido, Eduardo
dc.contributor.author Álava, Enrique de
dc.date.accessioned 2021-09-30T06:17:47Z
dc.date.available 2021-09-30T06:17:47Z
dc.date.issued 2022
dc.identifier.citation Conde E, Rojo F, Gómez J, Enguita AB, Abdulkader I, González A, Lozano D, Mancheño N, Salas C, Salido M, Salido-Ruiz E, de Álava E. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol. 2022;75(3):145-53. DOI: 10.1136/jclinpath-2021-207490
dc.identifier.issn 0021-9746
dc.identifier.uri http://hdl.handle.net/10230/48530
dc.description.abstract The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect genetic rearrangements in some genes (ie, ALK, ROS1, RET and NTRK) have become standard in patients with advanced disease. Since immunohistochemistry is easier to implement and interpret, it is normally used as the screening procedure, while fluorescence in situ hybridisation (FISH) is used to confirm the rearrangement and decide on ambiguous immunostainings. Although FISH is considered the most sensitive method for the detection of ALK and ROS1 rearrangements, the interpretation of results requires detailed guidelines. In this review, we discuss the various technologies available to evaluate ALK and ROS1 genomic rearrangements using these techniques. Other techniques such as real-time PCR and next-generation sequencing have been developed recently to evaluate ALK and ROS1 gene rearrangements, but some limitations prevent their full implementation in the clinical setting. Similarly, liquid biopsies have the potential to change the treatment of patients with advanced lung cancer, but further research is required before this technology can be applied in routine clinical practice. We discuss the technical requirements of laboratories in the light of quality assurance programmes. Finally, we review the recent updates made to the guidelines for the determination of molecular biomarkers in patients with NSCLC.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher BMJ Publishing Group
dc.relation.ispartof J Clin Pathol. 2022;75(3):145-53
dc.rights © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
dc.title Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1136/jclinpath-2021-207490
dc.subject.keyword Diagnostic techniques and procedures
dc.subject.keyword Immunohistochemistry
dc.subject.keyword Oncogenes
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking